Assembly Biosciences, Inc.
ASMBHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Valued at $404.0M, ASMB is a small-cap name in its sector. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Market Cap
$404.0M
Beta
1.16
P/E (TTM)
19.08
P/E (Fwd)
-7.71
EPS (TTM)
$1.04
EPS (Fwd)
$-2.57
ROE
-0.0%
ROA
-2.7%
Cash
$320.4M
Total Debt
$2.4M
Free CF
-$27.9M
52W Change
-33.4%
Annual Financials
Cash vs Debt
Where ASMB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ASMB finished 26.42% below its 150-day moving average ($27.40) and 27.25% below its 200-day moving average ($27.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ASMB overbought or oversold?
At the October 20, 2026 close, ASMB's RSI(14) was 27.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $320.4M in cash and $2.4M in debt, ASMB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$27.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -0.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, ASMB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Assembly Biosciences, Inc.'s trajectory.